Please login to the form below
cabozantinib
This page shows the latest cabozantinib news and features for those working in and with pharma, biotech and healthcare.
Merck’s Bavencio joins first-line kidney cancer face-off
Both combinations could challenge the position of Bristol-Myers Squibb’s Opdivo (nivolumab) and Yervoy (ipilimumab), which has started to replace Sutent and other TKIs like Exelixis’ Cabometyx (cabozantinib) as the
Latest news
-
NICE clears Ipsen’s Cabometyx in first-line kidney cancer
access cabozantinib earlier in their treatment pathway.”.
-
Pfizer’s plans for Inlyta go awry with failed adjuvant trial
nivolumab) and Exelixis’ multikinase inhibitor Cabometyx (cabozantinib) - backed by strong overall survival data - as well as Eisai’s multikinase drug Lenvima (lenvatinib).
-
FDA’s year-end approvals take annual tally to 46
Exelixis got the nod from the US regulator for Cabometyx (cabozantinib) as a first-line treatment for advanced renal cell carcinoma, giving the drug a boost against rival Sutent (sunitinib) from ... therapy. Analysts at Leerink have suggested the new
-
Ipsen’s liver cancer treatment clears phase III trial
Cabometyx on track for new liver cancer indication. Ipsen and partner Exelixis are on track to file cancer treatment Cabometyx (cabozantinib) for a new liver cancer indication in the first half ... Data showed cabozantinib provided a ‘statistically
-
NICE gives green light to Ipsen's Cabometyx
To date nearly 300 patients in the UK have benefited from cabozantinib through this Ipsen initiative, whilst the NICE process took place. ... We are delighted that now any eligible patient in the UK can benefit from cabozantinib.
More from news
Approximately 3 fully matching, plus 9 partially matching documents found.
Latest Intelligence
-
Charting a course for expansion
Cabometyx accelerates. Earlier this year Ipsen signed another deal to bolster its pipeline by harnessing external innovation, licensing promising cancer drug Cabometyx (cabozantinib) from Californian biotech Exelixis.
-
Deal Watch March 2016
marketed product Cometriq (cabozantinib). ... Collaboration – discovery, development &commercialisation. $965. Exelixis/ Ipsen. Cabozantinib (Renal Cell Carcinoma, Hepatocellular Carcinoma, other indications) and Cometriq (medullary thyroid cancer).
More from intelligence
Approximately 1 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
CABOSUN trial of cabozantinib – could it change how we treat frontline renal-cell carcinoma?
In the CABOSUN trial, cabozantinib was compared to sunitinib in treatment naive poor and intermediate risk renal-cell carcinoma (RCC) patients. ... Also, the secondary endpoint, response rate, was higher and more significant with cabozantinib.
More from PMHub
Approximately 1 fully matching, plus 0 partially matching documents found.
Featured jobs
- Account Manager / Senior Account Manager - Healthcare Advertisin...
-
Excellent Remuneration
- Freelance Medical Writer - Healthcare Advertising - London
-
Employment Type:. Type of Job:. Region:. Salary:. 250 to 330 per day
- Account Director – London based Medical Communications Agency
-
Excellent Remuneration Package
- Editor – Medical Education Agency – Bucks
-
Salary TBC
- Senior Account Manager- Pharma and Life Scienes
-
Competitive salary and benefits
- Project Manager - Digital Healthcare - London
-
Excellent Remuneration Package
-
Senior Medical Writer
-
Competitive salary and benefits
- Senior Account Director/ Associate Director- Pharma and Life Sci...
-
Competitive salary and benefits
-
Account Director, Medical Education
-
Salary TBC
-
Senior Medical Writer
-
Salary TBC
- Senior / Principal Medical Writer - MedComms - Home Based / Vari...
-
Excellent Remuneration Packages
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
- Project Manager - Medical Communications – South Wales
-
Excellent Remuneration Package
-
Director – Healthcare PR
-
Salary TBC
- Science Writer, Healthcare Advertising Agency
-
£40, 000 - 45, 000 DOE benefits,
- Experienced / Senior Account Director - Publications - London
-
Up to £80, 000 plus great benefits
Subscribe to our email news alerts
- With Spiriva under pressure, Boehringer moves to bolster pipeline
- Genfit claims FDA breakthrough status for liver disease drug
- Mereo’s shareholders back OncoMed takeover
- Lucid Group announces the appointment of new CFO
- From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
- Q&A: Niels Lund
PMHub
Streaming Well
Streaming Well is a healthcare focused, award-winning video production company which operates in the US and Europe....
Latest intelligence
- From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
- How pharma is progressing their commitment in patient engagement...
- Cuttsy+Cuttsy awarded CPD Platinum by the IPA
- Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
- Breaking Bad
- Six behaviours separate the good brand teams from the bad...
Quick links
Infographics
